Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Care
Hlavní autoři: Docherty, Kieran F., Jhund, Pardeep S., Bengtsson, Olof, DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., McMurray, John J.V.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2020
Témata:
Novel Communications in Diabetes
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809714/
https://ncbi.nlm.nih.gov/pubmed/33082245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-1402
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky